Specific protection against breast cancers by cyclin D1 ablation

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Nature

• Publication date

  2001-06-28

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/35082500PMID 11429595
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cyclin D1 Is Required for Transformation by Activated Neu and Is Induced through an E2F-Dependent Signaling Pathway

  2000cited by this paper
• Involvement of Myc Activity in a G1/S-Promoting Mechanism Parallel to the pRb/E2F Pathway

  2000cited by this paper
• Wnt1 and MEK1 Cooperate to Promote Cyclin D1 Accumulation and Cellular Transformation*

  2000cited by this paper
• Rescue of cyclin D1 deficiency by knockin cyclin E.

  1999cited by this paper
• Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells.

  1999cited by this paper
• CDK inhibitors: positive and negative regulators of G1-phase progression.

  1999cited by this paper
• Reduced skin tumor development in cyclin D1-deficient mice highlights the oncogenic ras pathway in vivo.

  1998cited by this paper
• Cyclin E and c‐Myc promote cell proliferation in the presence of p16INK4a and of hypophosphorylated retinoblastoma family proteins

  1997cited by this paper
• Cyclin D1 Expression Is Regulated Positively by the p42/p44MAPK and Negatively by the p38/HOGMAPK Pathway*

  1996cited by this paper
• Cyclin D2 is an FSH-responsive gene involved in gonadal cell proliferation and oncogenesis

  1996cited by this paper
• Cyclin D1 and prognosis in human breast cancer

  1996cited by this paper
• Determination of the prognostic value of cyclin D1 overexpression in breast cancer.

  1995cited by this paper
• Genetic alterations in breast cancer

  1995cited by this paper
• Amplification of chromosome band 11q13 and a role for cyclin D1 in human breast cancer.

  1995cited by this paper
• Ras transformation results in an elevated level of cyclin D1 and acceleration of G1 progression in NIH 3T3 cells

  1995cited by this paper
• Cyclin D2 is a moderately oscillating nucleoprotein required for G1 phase progression in specific cell types.

  1995cited by this paper
• Transforming p21ras Mutants and c-Ets-2 Activate the Cyclin D1 Promoter through Distinguishable Regions (*)

  1995cited by this paper
• Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions

  1995cited by this paper
• Mice lacking cyclin D1 are small and show defects in eye and mammary gland development.

  1995cited by this paper
• Induction of cyclin D1 overexpression by activated ras.

  1994cited by this paper
• Cyclin D1 protein expression and function in human breast cancer

  1994cited by this paper
• Activation of the Ras signalling pathway in human breast cancer cells overexpressing erbB-2.

  1994cited by this paper
• Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining.

  1994cited by this paper
• Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice

  1994cited by this paper
• Ocular findings in Angelman's (happy puppet) syndrome.

  1990cited by this paper
• Expression of the int-1 gene in transgenic mice is associated with mammary gland hyperplasia and adenocarcinomas in male and female mice.

  1988cited by this paper
• Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene.

  1988cited by this paper
• Prolactin regulation of beta‐casein gene expression and of a cytosolic 120‐kd protein in a cloned mouse mammary epithelial cell line.

  1988cited by this paper
• Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: synergistic action of oncogenes in vivo.

  1987cited by this paper
• Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185.

  1986cited by this paper
• Spontaneous mammary adenocarcinomas in transgenic mice that carry and express MTV/myc fusion genes.

  1984cited by this paper
• Correspondence and requests for materials should be addressed to M.L.L. (email:

  year unknowncited by this paper

• Cancer Cell Metastasis and Drug Resistance: Unravelling the Role of NF-κB and Cyclin D1 Pathways and Their Crosstalk.

  2026cites this paper
• Palbociclib for Hormone-Receptor-Positive, HER2-Positive Advanced Breast Cancer.

  2026cites this paper
• Phase I study of ribociclib (CDK4/6 inhibitor) with spartalizumab (PD-1 inhibitor) with and without fulvestrant in metastatic hormone receptor-positive breast cancer or advanced ovarian cancer

  2025cites this paper
• Overcoming Resistance to CDK4/6 inhibitors in Hormone Receptor positive, HER2 negative breast cancer: Innovative Combinations and Emerging Strategies.

  2025cites this paper
• Chromosome 8 Open Reading Frame 76 (C8orf76) Co-Expressed with Cyclin-Dependent Kinase 4 (CDK4) as a Prognostic Indicator of Colorectal Cancer.

  2025cites this paper
• Targeting the cell-cycle machinery for cancer therapy.

  2025cites this paper
• Cell cycle proteins: Linking the cell cycle to tumors

  2025cites this paper
• The receptor tyrosine kinase ErbB2/HER2 governs CDK4 inhibitor sensitivity, timing, and irreversibility of the G1/S transition

  2025cites this paper
• Differentially localized protein identification for breast cancer based on deep learning in immunohistochemical images

  2024cites this paper
• The role of C1orf50 in breast cancer progression and prognosis

  2024cites this paper
• Disruption of cyclin D1 degradation leads to the development of mantle cell lymphoma

  2024cites this paper
• PC4: A new regulator of cyclin D1 transcript levels

  2024cites this paper
• A cyclin D1 intrinsically disordered domain accesses modified histone motifs to govern gene transcription

  2024cites this paper
• Wortmannin Inhibits Cell Growth and Induces Apoptosis in Colorectal Cancer Cells by Suppressing the PI3K/AKT Pathway.

  2024cites this paper
• Advances in the study of marketed antibody-drug Conjugates (ADCs) for the treatment of breast cancer

  2024cites this paper
• No QTc prolongation with CDK 4/6 inhibitor FCN-437c: results of a concentration-QTc analysis from a dedicated study in adult healthy subjects

  2024cites this paper
• The oncogene cyclin D1 promotes bipolar spindle integrity under compressive force

  2024cites this paper
• Insight into mammary gland development and tumor progression in an E2F5 conditional knockout mouse model

  2024cites this paper
• Allyl isothiocyanate regulates oxidative stress, inflammation, cell proliferation, cell cycle arrest, apoptosis, angiogenesis, invasion and metastasis via interaction with multiple cell signaling pathways

  2023cites this paper
• Targeting protein tyrosine phosphatases for CDK6-induced immunotherapy resistance

  2023cites this paper
• Cell facilitation promotes growth and survival under drug pressure in breast cancer

  2023cites this paper
• Aberrant Cyclin D1 splicing in cancer: from molecular mechanism to therapeutic modulation

  2023cites this paper
• Cellular senescence: a double-edged sword in cancer therapy

  2023cites this paper
• Cyclin‐dependent kinases: Masters of the eukaryotic universe

  2023cites this paper
• Transcriptome profiling and network enrichment analyses identify subtype-specific therapeutic gene targets for breast cancer and their microRNA regulatory networks

  2023cites this paper
• Monitoring the Cell Cycle of Tumor Cells in Mouse Models of Human Cancer.

  2023cites this paper
• The oncogene cyclin D1 promotes bipolar spindle integrity under compressive force

  2023cites this paper
• [Biological, preclinical and clinical aspects of the association between radiation therapy and CDK4/6 inhibitors].

  2023cites this paper
• Evolving perspectives on the treatment of HR+/HER2+ metastatic breast cancer

  2023cites this paper
• Inhibiting CDK4/6 in pancreatic ductal adenocarcinoma via microRNA-21.

  2023cites this paper
• Autophagy and Breast Cancer: Connected in Growth, Progression, and Therapy

  2023cites this paper
• The Evolving Pathways of the Efficacy of and Resistance to CDK4/6 Inhibitors in Breast Cancer

  2023cites this paper
• Emerging Therapies for Breast Cancer.

  2022cites this paper
• Herbal Ingredients in the Prevention of Breast Cancer: Comprehensive Review of Potential Molecular Targets and Role of Natural Products

  2022cites this paper
• Regulation of Cyclin D1 Degradation by Ubiquitin Specific Protease 27X is Critical for Cancer Cell Proliferation and Tumor Growth.

  2022cites this paper
• Combined epigenetic and immunotherapy for blastic and classical mantle cell lymphoma

  2022cites this paper
• Inhibition of the Wnt/b-catenin pathway using PNU-74654 reduces tumor growth in in vitro and in vivo models of colorectal cancer.

  2022cites this paper
• CDK4: a master regulator of the cell cycle and its role in cancer

  2022influential citation
• Bridged Proteolysis Targeting Chimera (PROTAC) Enables Degradation of Undruggable Targets.

  2022cites this paper
• Immunohistochemical Overexpression of Cyclin D1 in Tunisian Invasive Breast Carcinoma Women

  2022cites this paper
• Cyclin-Dependent Kinase 4 and 6 Inhibitors as Breast Cancer Therapy: Research Progress and Prospects

  2022cites this paper
• Science Journals — AAAS

  2022cites this paper
• The Emerging Role of Cyclin-Dependent Kinase Inhibitors in Treating Diet-Induced Obesity: New Opportunities for Breast and Ovarian Cancers?

  2022cites this paper
• Cellular mechanisms underlying response and resistance to CDK4/6 inhibitors in the treatment of hormone receptor-positive breast cancer

  2022cites this paper
• CDK4/6 Inhibitors in Combination Therapies: Better in Company Than Alone: A Mini Review

  2022cites this paper
• CDK4 and CDK6 kinases: From basic science to cancer therapy

  2022cites this paper
• Targeting CDK4 and CDK6 in cancer

  2022cites this paper
• Serial circulating tumor DNA monitoring of CDK4/6 inhibitors response in metastatic breast cancer

  2022cites this paper
• Modulation of the Estrogen/erbB2 Receptors Cross-talk by CDK4/6 Inhibition Triggers Sustained Senescence in Estrogen Receptor– and ErbB2-positive Breast Cancer

  2022cites this paper
• Cyclin-Dependent Kinase 4/6 Inhibitors: A Potential Breakthrough Therapy for Malignancies of Gastrointestinal Tract

  2022cites this paper
• Cellular senescence and the tumour microenvironment

  2022cites this paper
• Inhibition of CDK4/6 as Therapeutic Approach for Ovarian Cancer Patients: Current Evidences and Future Perspectives

  2021cites this paper
• The evolution of cyclin dependent kinase inhibitors in the treatment of cancer

  2021cites this paper
• The Involvement of Ubiquitination Machinery in Cell Cycle Regulation and Cancer Progression

  2021cites this paper
• Proteogenomic approach to drug targets in osteosarcomas with different original sites

  2021cites this paper
• Potential Prospect of CDK4/6 Inhibitors in Triple-Negative Breast Cancer

  2021cites this paper
• The Role of Intrinsic Signaling Pathways in Cell Proliferation

  2021cites this paper
• Ecological interactions in breast cancer: Cell facilitation promotes growth and survival under drug pressure

  2021cites this paper
• Cyclin-dependent kinase 4 and 6 inhibitors at the crossroads: the combinational therapeutic strategies in breast cancer—a narrative review

  2021cites this paper
• Transcriptional Repression of MFG-E8 Causes Disturbance in the Homeostasis of Cell Cycle Through DOCK/ZP4/STAT Signaling in Buffalo Mammary Epithelial Cells

  2021cites this paper
• The Discovery of Kisqali ® (Ribociclib): A CDK 4/6 Inhibitor for the Treatment of HR +/ HER 2− Advanced Breast Cancer

  2021cites this paper
• Complement factor B regulates cellular senescence and is associated with poor prognosis in pancreatic cancer

  2021cites this paper
• Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer

  2021cites this paper
• Triple Targeting of Breast Tumors Driven by Hormonal Receptors and HER2

  2021cites this paper
• Research Progress on the Role of Regulatory T Cell in Tumor Microenvironment in the Treatment of Breast Cancer

  2021cites this paper
• Zotatifin, an eIF4A-Selective Inhibitor, Blocks Tumor Growth in Receptor Tyrosine Kinase Driven Tumors

  2021cites this paper
• A quantitative systems pharmacological approach identified activation of JNK signaling pathway as a promising treatment strategy for refractory HER2 positive breast cancer

  2021cites this paper
• Understanding and overcoming tumor heterogeneity in metastatic breast cancer treatment

  2021cites this paper
• Insight into mammary gland development and tumor prevention in a newly developed metastatic mouse model of breast cancer

  2021cites this paper
• The Effects of HER2 on CDK4/6 Activity in Breast Cancer.

  2021cites this paper
• Restoring order at the cell cycle border: Co-targeting CDK4/6 and CDK2.

  2021cites this paper
• CDK4 has the ability to regulate Aurora B and Cenpp expression in mouse keratinocytes

  2021cites this paper
• Implications of TGFβ Signaling and CDK Inhibition for the Treatment of Breast Cancer

  2021cites this paper
• The Multifaced Role of STAT3 in Cancer and Its Implication for Anticancer Therapy

  2021cites this paper
• Cyclin D1 promotes secretion of pro-oncogenic immuno-miRNAs and piRNAs.

  2020cites this paper
• Analysis of HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinomas and Paired Normal Mucosae Reveals Cyclin D1 Deregulation and Compensatory Effect of Cyclin D2

  2020cites this paper
• Strategies for Increasing the Effectiveness of Aromatase Inhibitors in Locally Advanced Breast Cancer: An Evidence-Based Review on Current Options

  2020cites this paper
• BAP18 is involved in upregulation of CCND1/2 transcription to promote cell growth in oral squamous cell carcinoma

  2020cites this paper
• Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future.

  2020cites this paper
• Mechanisms of Sensitivity and Resistance to CDK4/6 Inhibition.

  2020cites this paper
• CDK4/6 and MAPK—Crosstalk as Opportunity for Cancer Treatment

  2020influential citation
• Cyclin D1 in Cancer: A Molecular Connection for Cell Cycle Control, Adhesion and Invasion in Tumor and Stroma

  2020cites this paper
• Abemaciclib as an original inhibitor of cyclin-dependent kinase for the treatment of luminal HER2-negative disseminated breast cancer

  2020cites this paper
• An evaluation of palbociclib as a breast cancer treatment option: a current update

  2020cites this paper
• Differential Regulation of Cancer Progression by CDK4/6 Plays a Central Role in DNA Replication and Repair Pathways

  2020cites this paper
• Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLTI-1303 PATRICIA Trial

  2020cites this paper
• The requirement for cyclin E in c-Myc overexpressing breast cancers

  2020cites this paper
• The root cause of drug resistance in HER2-positive breast cancer and the therapeutic approaches to overcoming the resistance.

  2020cites this paper
• In vivo modeling of the EGFR family in breast cancer progression and therapeutic approaches.

  2020cites this paper
• Arctigenin inhibits proliferation of ER-positive breast cancer cells through cell cycle arrest mediated by GSK3-dependent cyclin D1 degradation.

  2020cites this paper
• Ribociclib plus fulvestrant in the treatment of breast cancer

  2020cites this paper
• Abemaciclib, a CDK4 and CDK6 inhibitor for the treatment of metastatic breast cancer.

  2020cites this paper
• Exploring the Role of Novel Medical Therapies for Aggressive Pituitary Tumors: A Review of the Literature—“Are We There Yet?”

  2020cites this paper
• Current Therapeutic Progress of CDK4/6 Inhibitors in Breast Cancer

  2020cites this paper
• Senescent Cells in Cancer Therapy: Friends or Foes?

  2020cites this paper
• Biomarkers from Bench to Bedside and Back – Back‐Translation of Clinical Studies to Preclinical Models

  2020cites this paper
• Less-well known functions of cyclin/CDK complexes.

  2020cites this paper
• Atypical cyclins in cancer: New kids on the block?

  2020cites this paper
• Cyclin D1 and PSA act as good prognostic and clinicopathological indicators for breast cancer

  2020cites this paper
• Therapy after cyclin‐dependent kinase inhibition in metastatic hormone receptor‐positive breast cancer: Resistance mechanisms and novel treatment strategies

  2020cites this paper